Aliases & Classifications for Pituitary Gland Disease

MalaCards integrated aliases for Pituitary Gland Disease:

Name: Pituitary Gland Disease 12 15
Pituitary Dysfunction 55 73
Pituitary Diseases 55 73
Pituitary Disorders 43
Pituitary Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:53
ICD9CM 35 253.1
ICD10 33 E23.6

Summaries for Pituitary Gland Disease

MedlinePlus : 43 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. With pituitary disorders, you often have too much or too little of one of your hormones. Injuries can cause pituitary disorders, but the most common cause is a pituitary tumor.

MalaCards based summary : Pituitary Gland Disease, also known as pituitary dysfunction, is related to empty sella syndrome and mccune-albright syndrome, and has symptoms including back pain, headache and pain. An important gene associated with Pituitary Gland Disease is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and p70S6K Signaling. The drugs Zinc and Menthol have been mentioned in the context of this disorder. Affiliated tissues include the pituitary gl, pituitary and brain, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 An endocrine system disease that is located in the pituitary gland.

Wikipedia : 76 In vertebrate anatomy, the pituitary gland, or hypophysis, is an endocrine gland about the size of a pea... more...

Related Diseases for Pituitary Gland Disease

Diseases related to Pituitary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 empty sella syndrome 31.1 GH1 GNRH1 IGF1 POMC PRL
2 mccune-albright syndrome 29.7 GH1 IGF1 PRL SST
3 growth hormone deficiency 29.2 GH1 GHRH HESX1 IGF1
4 multiple endocrine neoplasia, type i 28.5 GHRH INS MEN1 PRL SST
5 acromegaly 27.2 GH1 GHRH IGF1 INS MEN1 POMC
6 hypopituitarism 25.7 CRH GH1 GHRH GNRH1 HESX1 IGF1
7 microphthalmia, syndromic 5 11.7
8 pallister-hall syndrome 11.0
9 fibrous dysplasia/mccune-albright syndrome 10.9 GH1 PRL
10 galactorrhea 10.9 IGF1 PRL
11 optic nerve hypoplasia, bilateral 10.8
12 laurence-moon syndrome 10.8
13 hypothyroidism, central, and testicular enlargement 10.8
14 culler-jones syndrome 10.8
15 lymphocytic hypophysitis 10.8 GH1 POMC
16 bronchus adenoma 10.8 POMC SST
17 non-functioning pituitary adenoma 10.8 GH1 SST
18 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.7 IGF1 INS
19 pseudohypoparathyroidism, type ia 10.7 GH1 IGF1 PRL
20 scleredema adultorum 10.7 INS POMC
21 prolactin producing pituitary tumor 10.7 PRL SST
22 froelich syndrome 10.7
23 neonatal thyrotoxicosis 10.6 LHX3 PROP1
24 adenohypophysitis 10.6 GH1 POMC PRL
25 pancreatic gastrinoma 10.6 MEN1 SST
26 tsh producing pituitary tumor 10.6 GH1 PRL SST
27 acidophil adenoma 10.6 IGF1 POMC SST
28 duodenal somatostatinoma 10.6 INS SST
29 endometriosis of uterus 10.6 GNRH1 PRL
30 postgastrectomy syndrome 10.6 INS SST
31 pancreatic somatostatinoma 10.6 MEN1 SST
32 postural hypotension 10.6 INS SST
33 hypogonadotropism 10.6 GNRH1 PRL
34 acanthosis nigricans 10.5 IGF1 INS PRL
35 central nervous system germinoma 10.5 AVP POMC
36 central precocious puberty 10.5 GNRH1 IGF1
37 tuberculous epididymitis 10.5 AVP POMC
38 hormone producing pituitary cancer 10.5 IGF1 MEN1 SST
39 overnutrition 10.4 IGF1 INS POMC
40 central nervous system germ cell tumor 10.4 AVP POMC
41 fasting hypoglycemia 10.4 CRH IGF1 POMC
42 acth-secreting pituitary adenoma 10.4 CRH POMC PRL
43 hypoadrenalism 10.4 CRH GH1 POMC
44 persistent fetal circulation syndrome 10.4 CRH IGF1 POMC
45 mammographic density 10.4 IGF1 PRL
46 acth deficiency, isolated 10.4 CRH POMC
47 melancholia 10.4 CRH PRL
48 pituitary adenoma 1, multiple types 10.4 GH1 IGF1 PRL SST
49 inappropriate adh syndrome 10.4 AVP POMC
50 chronic fatigue syndrome 10.4 CRH IGF1 POMC

Graphical network of the top 20 diseases related to Pituitary Gland Disease:



Diseases related to Pituitary Gland Disease

Symptoms & Phenotypes for Pituitary Gland Disease

UMLS symptoms related to Pituitary Gland Disease:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Pituitary Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.21 HESX1 IGF1 CRH INS GHRH LHX3
2 growth/size/body region MP:0005378 10.18 MEN1 HESX1 IGF1 CRH INS GHRH
3 homeostasis/metabolism MP:0005376 10.18 AVP IGF1 CRH INS GHRH LHX3
4 immune system MP:0005387 10.02 GNRH1 MEN1 IGF1 CRH INS GHRH
5 nervous system MP:0003631 10 HESX1 POMC IGF1 AVP CRH INS
6 liver/biliary system MP:0005370 9.8 MEN1 CRH INS GHRH GNRH1 POMC
7 renal/urinary system MP:0005367 9.43 GNRH1 AVP IGF1 CRH INS POMC
8 reproductive system MP:0005389 9.28 MEN1 IGF1 INS GHRH LHX3 GNRH1

Drugs & Therapeutics for Pituitary Gland Disease

Drugs for Pituitary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 593)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 7440-66-6 23994
2
Menthol Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
4
Metyrapone Approved, Investigational Phase 4,Phase 3 54-36-4 4174
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
6
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 81409-90-7 54746
7
Ganirelix Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123246-29-7, 124904-93-4 25081094
8 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
9
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
10
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
11
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
12
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
13
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
14
Tolvaptan Approved Phase 4,Phase 3,Phase 1,Phase 2 150683-30-0 216237
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
16
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 5949-44-0
17 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
18
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
19
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
20
Leuprolide Approved, Investigational Phase 4,Not Applicable 53714-56-0 3911 657181
21
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
22
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-18-4 6010
23
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
24
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
25
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
26
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
27
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 315-37-7 9416
28
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 120511-73-1 2187
29
Pioglitazone Approved, Investigational Phase 4,Early Phase 1,Not Applicable 111025-46-8 4829
30
Norgestrel Approved Phase 4,Phase 3 6533-00-2 13109
31
Quinagolide Approved, Investigational Phase 4 97805-50-0, 87056-78-8 105105
32
Morphine Approved, Investigational Phase 4 57-27-2 5288826
33
Clobetasol Approved, Investigational Phase 4,Phase 2 25122-46-7, 25122-41-2 32798 5311051
34
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
35
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 113775-47-6 68602 5311068
36
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
37
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
38
Acetaminophen Approved Phase 4 103-90-2 1983
39
Ibuprofen Approved Phase 4 15687-27-1 3672
40
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Not Applicable 797-63-7, 17489-40-6 13109
41
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
42
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
43
Cetrorelix Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 120287-85-6 16129715 25074887
44
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
45
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
46
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
47
Sodium oxybate Approved Phase 4 502-85-2 5360545
48
Desoximetasone Approved Phase 4,Phase 2 382-67-2 5311067
49
Cosyntropin Approved Phase 4,Phase 1,Not Applicable 16960-16-0 16129617
50
Menotropins Approved Phase 4,Phase 2,Not Applicable 61489-71-2, 9002-68-0 5360545

Interventional clinical trials:

(show top 50) (show all 1040)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
3 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
4 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
5 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
6 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
7 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
8 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
9 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
10 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
11 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
12 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
13 Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis Completed NCT01154153 Phase 4 Placebo nasal spray;Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ);Placebo nasal spray;Claritin® Syrup
14 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
15 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
16 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
17 Testosterone Gel Applied to Women With Pituitary Gland Problems Completed NCT00144391 Phase 4 Transdermal Testosterone gel
18 Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population Completed NCT01137032 Phase 4 Pandel Cream 0.1%
19 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
20 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
21 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
22 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
23 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
24 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
25 Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) Completed NCT00449072 Phase 4 TAA-AQ, Nasacort® AQ;Claritin®
26 Effect of DPP4 Inhibition on Growth Hormone Secretion Completed NCT01701973 Phase 4 Sitagliptin;Pegvisomant;Placebo;L-NMMA;Exendin 9-39
27 Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study Completed NCT02204826 Phase 4 Korean Red Ginseng (KRG)
28 Viapaed Study In Children And Adolescents With Asthma Completed NCT00315744 Phase 4 Salmeterol/fluticasone;Fluticasone propionate;Salbutamol
29 Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF) Completed NCT01225835 Phase 4 Menotrophin;Follitrophin alpha;Cetrorelix;Choriongonadotropin;Progesterone
30 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
31 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
32 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
33 Easypod United States User Trial Completed NCT00689260 Phase 4
34 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
35 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
36 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
37 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
38 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
39 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
40 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
41 IGF1 Generation Test Completed NCT00145457 Phase 4
42 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
43 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
44 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
45 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
46 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
47 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
48 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) Completed NCT01546922 Phase 4 Hydrocortisone
49 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
50 IVF/ICSI Protocols in Poor Responders With Growth Hormone Completed NCT01897324 Phase 4 Growth hormone (Norditropin, Novo nordisk)

Search NIH Clinical Center for Pituitary Gland Disease

Genetic Tests for Pituitary Gland Disease

Anatomical Context for Pituitary Gland Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Pituitary Gland Disease:

19
The Pituitary Gl

MalaCards organs/tissues related to Pituitary Gland Disease:

41
Pituitary, Brain, Testes, Bone, Ovary, Thyroid, Heart

Publications for Pituitary Gland Disease

Articles related to Pituitary Gland Disease:

(show all 40)
# Title Authors Year
1
Sellar plasmacytoma presenting with symptoms of anterior pituitary dysfunction. ( 29204279 )
2017
2
IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction. ( 27083162 )
2016
3
Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury. ( 26252757 )
2015
4
Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction. ( 23904277 )
2013
5
Post-traumatic head injury pituitary dysfunction. ( 22779906 )
2013
6
Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. ( 21832120 )
2011
7
Irreformable hyponatremia: a case report of pituitary dysfunction with liver cirrhosis. ( 21933634 )
2011
8
Prevalence of anterior pituitary dysfunction in patients following traumatic brain injury in a German multi-centre screening program. ( 19691014 )
2010
9
Obstructive prosthetic atrioventricular valve thrombosis in a woman with congenitally corrected transposition of the great arteries during estrogen replacement therapy for pituitary dysfunction. ( 20058140 )
2010
10
A rare de novo nonsense mutation in OTX2 causes early onset retinal dystrophy and pituitary dysfunction. ( 19956411 )
2009
11
Does the type and severity of brain injury predict hypothalamo-pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome? ( 18404391 )
2008
12
Oliver-McFarlane syndrome (chorioretinopathy-pituitary dysfunction) with prominent early pituitary dysfunction: differentiation from choroideremia-hypopituitarism. ( 18978655 )
2008
13
Apolipoprotein E3/E3 genotype decreases the risk of pituitary dysfunction after traumatic brain injury due to various causes: preliminary data. ( 18707245 )
2008
14
Longitudinal study of patients with idiopathic isolated TSH deficiency: possible progression of pituitary dysfunction in lymphocytic adenohypophysitis. ( 16896268 )
2006
15
Transient pituitary dysfunction, empty sella, pseudotumor cerebri in a morbidly obese adolescent. ( 17237746 )
2006
16
Post-traumatic anterior and posterior pituitary dysfunction. ( 16091821 )
2005
17
Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. ( 16144946 )
2005
18
Autosomal recessive Oliver-McFarlane syndrome: retinitis pigmentosa, short stature (GH deficiency), trichomegaly, and hair anomalies or CPD syndrome (chorioretinopathy-pituitary dysfunction). ( 16152639 )
2005
19
Weber-Christian disease and pituitary dysfunction in a patient with polymyositis. ( 15638065 )
2004
20
Occurrence of pituitary dysfunction following traumatic brain injury. ( 15253797 )
2004
21
Reversible pituitary dysfunction in a patient with Cushing's syndrome discovered as adrenal incidentaloma. ( 15118271 )
2004
22
Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. ( 9988269 )
1999
23
A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. ( 9537324 )
1998
24
Pituitary dysfunction in recently post-menopausal women. Nottingham EPIC Study Group. ( 9404441 )
1997
25
Development of prostate cancer after pituitary dysfunction: a report of 8 patients. ( 9111626 )
1997
26
A case of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes associated with diabetes mellitus and hypothalamo-pituitary dysfunction. ( 9622295 )
1997
27
Hypothalamic-pituitary dysfunction in patients with craniopharyngioma. ( 7621564 )
1995
28
An association between hypothalamic-pituitary dysfunction and peripheral endocrine function in extreme obesity. ( 1889145 )
1991
29
Hypothalamo-pituitary dysfunction in congenital toxoplasmosis. ( 2792124 )
1989
30
Hypothalamic-pituitary dysfunction in polycystic ovarian disease. ( 3143565 )
1988
31
Hypothalamic-pituitary dysfunction and Hirschsprung's disease in the Bardet-Biedl syndrome. ( 3065301 )
1988
32
A case of Klinefelter's syndrome associated with hypothalamic-pituitary dysfunction caused by an intracranial germ cell tumor. ( 2440666 )
1987
33
Hypothalamic-pituitary dysfunction in primary empty sella syndrome in childhood. ( 3958827 )
1986
34
Reversible panhypopituitarism caused by a suprasellar aneurysm: the contribution of mass effect to pituitary dysfunction. ( 6808414 )
1982
35
A variant of adrenomyeloneuropathy with hypothalamic-pituitary dysfunction and neurologic remission after glucocorticoid replacement therapy. ( 6277189 )
1982
36
The syndrome of basal encephalocele and hypothalamic-pituitary dysfunction. ( 717987 )
1978
37
Co-existent eosinophilic gastroenteritis and hypothalamic-pituitary dysfunction. ( 882484 )
1977
38
Hypothalamic-pituitary dysfunction following group B beta hemolytic streptococcal meningitis in a neonate. ( 765442 )
1976
39
Cleft lip and chorioideal coloboma associated with multiple hypothalamo-pituitary dysfunctions. ( 5002717 )
1971
40
A RARE FORM OF RETINO-CHOROIDITIS, POSSIBLY ASSOCIATED WITH PITUITARY DYSFUNCTION. ( 18168414 )
1924

Variations for Pituitary Gland Disease

Expression for Pituitary Gland Disease

Search GEO for disease gene expression data for Pituitary Gland Disease.

Pathways for Pituitary Gland Disease

GO Terms for Pituitary Gland Disease

Cellular components related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 AVP CRH GH1 GHRH GNRH1 IGF1
2 extracellular space GO:0005615 9.32 AVP CRH GH1 GHRH GNRH1 IGF1
3 endosome lumen GO:0031904 9.13 GH1 INS PRL

Biological processes related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 AVP CRH IGF1 INS
2 negative regulation of apoptotic process GO:0043066 9.88 AVP GNRH1 IGF1 INS LHX3 PROP1
3 cellular protein metabolic process GO:0044267 9.83 IGF1 INS MEN1 PRL
4 response to ethanol GO:0045471 9.77 AVP CRH GNRH1
5 glucose homeostasis GO:0042593 9.75 IGF1 INS POMC
6 female pregnancy GO:0007565 9.73 CRH GNRH1 PRL
7 cell-cell signaling GO:0007267 9.73 AVP GHRH GNRH1 INS POMC SST
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.72 GH1 IGF1 INS
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 GH1 IGF1 INS
10 positive regulation of multicellular organism growth GO:0040018 9.63 GH1 GHRH POU1F1
11 positive regulation of glycolytic process GO:0045821 9.62 IGF1 INS
12 response to nutrient levels GO:0031667 9.62 GH1 IGF1 INS PRL
13 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.61 AVP IGF1
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.61 IGF1 INS
15 pituitary gland development GO:0021983 9.61 HESX1 LHX3 POU1F1
16 positive regulation of glycogen biosynthetic process GO:0045725 9.59 IGF1 INS
17 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 GH1 PRL
18 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.54 GH1 GHRH IGF1
19 hormone-mediated apoptotic signaling pathway GO:0008628 9.51 CRH SST
20 positive regulation of cell proliferation GO:0008284 9.5 AVP CRH GHRH IGF1 INS POU1F1
21 somatotropin secreting cell differentiation GO:0060126 9.48 POU1F1 PROP1
22 adenohypophysis development GO:0021984 9.33 GHRH POU1F1 PROP1
23 regulation of signaling receptor activity GO:0010469 9.28 AVP GH1 GHRH GNRH1 IGF1 INS
24 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 IGF1 LHX3 MEN1 POMC POU1F1 PROP1
25 G-protein coupled receptor signaling pathway GO:0007186 10.04 AVP CRH GHRH GNRH1 INS POMC

Molecular functions related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.37 IGF1 INS
2 neuropeptide hormone activity GO:0005184 9.33 AVP CRH POMC
3 insulin-like growth factor receptor binding GO:0005159 9.32 IGF1 INS
4 hormone activity GO:0005179 9.28 AVP CRH GH1 GNRH1 IGF1 INS
5 receptor activator activity GO:0030546 9.26 IGF1 INS
6 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....